Radiotherapy & Oncology
Volume 95, Issue 3 , Pages 312-316 , June 2010

Low locoregional recurrence rates in patients treated after 2000 with doxorubicin based chemotherapy, modified radical mastectomy, and post-mastectomy radiation

  • Michael P. Greenbaum

      Affiliations

    • The Methodist Hospital, Houston, TX, USA
    • ,
  • Eric A. Strom

      Affiliations

    • Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
    • ,
  • Pamela K. Allen

      Affiliations

    • Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
    • ,
  • George H. Perkins

      Affiliations

    • Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
    • ,
  • Julia L. Oh

      Affiliations

    • Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
    • ,
  • Welela Tereffe

      Affiliations

    • Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
    • ,
  • Tse-Kuan Yu

      Affiliations

    • Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
    • ,
  • Thomas A. Buchholz

      Affiliations

    • Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
    • ,
  • Wendy. A. Woodward

      Affiliations

    • Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
    • Corresponding Author InformationCorresponding author. Address: The University of Texas M. D. Anderson Cancer Center Department of Radiation Oncology, Unit 1202, 1515 Holcombe Blvd, Houston, TX 77005, United States.

Received 16 March 2009 ,Revised 15 February 2010 ,Accepted 17 February 2010.

References 

  1. Overgaard M, Hansen PS, Overgaard J, et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med. 1997;337:949–955
  2. Ragaz J, Olivotto IA, Spinelli JJ, et al. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. J Natl Cancer Inst. 2005;97:116–126
  3. Overgaard M, Jensen MB, Overgaard J, et al. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet. 1999;353:1641–1648
  4. Buzdar AU, Blumenschein GR, Smith TL, et al. Adjuvant chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide, with or without Bacillus Calmette-Guerin and with or without irradiation in operable breast cancer. A prospective randomized trial. Cancer. 1984;53:384–389
  5. Buzdar AU, Blumenschein GR, Montague ED, et al. Combined modality approach in breast cancer with isolated or multiple metastases. Am J Clin Oncol. 1984;7:45–50
  6. Buzdar AU, Hortobagyi GN, Marcus CE, Smith TL, Martin R, Gehan EA. Results of adjuvant chemotherapy trials in breast cancer at M. D. Anderson Hospital and Tumor Institute. NCI Monogr. 1986;81–85
  7. Buzdar AU, Hortobagyi GN, Smith TL, et al. Adjuvant therapy of breast cancer with or without additional treatment with alternate drugs. Cancer. 1988;62:2098–2104
  8. Buzdar AU, Kau SW, Smith TL, Hortobagyi GN. Ten-year results of FAC adjuvant chemotherapy trial in breast cancer. Am J Clin Oncol. 1989;12:123–128
  9. Buzdar AU, Hortobagyi GN, Kau SW, et al. Adjuvant therapy with escalating doses of doxorubicin and cyclophosphamide with or without leukocyte alpha-interferon for stage II or III breast cancer. J Clin Oncol. 1992;10:1540–1546
  10. Theriault R, Buzdar AU, Hortobagyi GN, et al. Irradiation (XRT) following mastectomy in patients treated with FAC adjuvant therapy—MD Anderson Cancer Center experience. Proc Am Soc Clin Oncol. 1998;10:(abstr 381)
  11. Woodward WA, Strom EA, Tucker SL, et al. Locoregional recurrence after doxorubicin-based chemotherapy and postmastectomy: implications for breast cancer patients with early-stage disease and predictors for recurrence after postmastectomy radiation. Int J Radiat Oncol Biol Phys. 2003;57:336–344
  12. Huang EH, Tucker SL, Strom EA, et al. Postmastectomy radiation improves local-regional control and survival for selected patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy. J Clin Oncol. 2004;22:4691–4699
  13. The World Health Organization Histological Typing of Breast Tumors—Second Edition. Am J Clin Pathol 1982;78:806–16.
  14. Black MM, Speer FD. Nuclear structure in cancer tissues. Surg Gynecol Obstet. 1957;105:97–102
  15. Harris E, Albert A. Estimating survival probabilities. In:  Harris E,  Albert A editor. Survivorship analysis for clinical studies. New York: Marcel Dekker, Inc.; 1991;p. 3–35
  16. Clarke M, Collins R, Darby S, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;366:2087–2106
  17. Bauduceau O, Bollet MA, Pons P, et al. The use of computed tomography in radiotherapy treatment planning for breast cancer. How does conventional radiotherapy planning compare with virtual?. J Buon. 2008;13:245–251
  18. Thomsen MS, Berg M, Nielsen HM, et al. Post-mastectomy radiotherapy in Denmark: from 2D to 3D treatment planning guidelines of The Danish Breast Cancer Cooperative Group. Acta Oncol. 2008;47:654–661
  19. Perkins GH, McNeese MD, Antolak JA, Buchholz TA, Strom EA, Hogstrom KR. A custom three-dimensional electron bolus technique for optimization of postmastectomy irradiation. Int J Radiat Oncol Biol Phys. 2001;51:1142–1151
  20. Krueger EA, Fraass BA, McShan DL, Marsh R, Pierce LJ. Potential gains for irradiation of chest wall and regional nodes with intensity modulated radiotherapy. Int J Radiat Oncol Biol Phys. 2003;56:1023–1037
  21. Sartor CI, Peterson BL, Woolf S, et al. Effect of addition of adjuvant paclitaxel on radiotherapy delivery and locoregional control of node-positive breast cancer: cancer and leukemia group B 9344. J Clin Oncol. 2005;23:30–40
  22. Feinstein AR, Sosin DM, Wells CK. The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. N Engl J Med. 1985;312:1604–1608
  23. Woodward WA, Strom EA, Tucker SL, et al. Changes in the 2003 American Joint Committee on Cancer staging for breast cancer dramatically affect stage-specific survival. J Clin Oncol. 2003;21:3244–3248

PII: S0167-8140(10)00106-4

doi: 10.1016/j.radonc.2010.02.013

Radiotherapy & Oncology
Volume 95, Issue 3 , Pages 312-316 , June 2010

Article Tools

* Image Usage & Resolution